Despite advances in anticoagulant therapies, bleeding remains a critical concern.Traditionally, the definition of major ...

Data taken from [59–62]. Warfarin is the most well-understood oral anticoagulant in terms of genetics. CYP2C9 and VKORC1 polymorphisms lead to variable dose response and complicate warfarin therapy.

A placebo-controlled phase 3 trial of asundexian in older patients who aren’t eligible for directly-acting oral anticoagulants ... in patients in need of antithrombotic treatment,” said ...

Pulmonary embolism is a common cause of cardiovascular-associated morbidity and mortality. Although pulmonary embolism ...

AstraZeneca's anticoagulant reversal agent Andexxa was given an accelerated approval by the FDA in 2018, but the company's plan to get that upgraded to a full approval is facing some pushback.

These states and circumstances can often be modified, for example, by improving the benefit : risk ratio by closer anticoagulant monitoring ... preferences of patients and their physicians for ...

Influence of depression trajectories in heart failure patients with preserved ejection fractions: a secondary analysis of adverse outcomes in the TOPCAT trial ...